SCHEMBL23950568

SCHEMBL23950568

CC(O)Cn1cnc2c(-c3cnn(C)c3)nc(-c3cnn(C)c3)cc2c1=O

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM5B Q9UGL1 3/20 0.39
PIM1 P11309 3/20 0.39
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RET P07949 2/20 0.36
JAK2 O60674 4/20 0.36
JAK1 P23458 4/20 0.36
TYK2 P29597 4/20 0.36
JAK3 P52333 4/20 0.36
PIK3CA P42336 2/20 0.36
MTOR P42345 2/20 0.36
FGFR1 P11362 2/20 0.35
FGFR2 P21802 2/20 0.35
FGFR3 P22607 2/20 0.35
USP7 Q93009 1/20 0.35
SYK P43405 1/20 0.35
MAP4K1 Q92918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23925521 0.92 AHR (0.38) KDM5BSMN1; SMN2RETFGFR3USP7
SCHEMBL26275672 0.92 SYK (0.37) KDM5BRETJAK2JAK1TYK2
SCHEMBL26275665 0.92 SYK (0.37) KDM5BRETJAK2JAK1TYK2
SCHEMBL25405329 0.90 KDM5B (0.39) KDM5BLMNASMN1; SMN2PIK3CAMTOR
SCHEMBL25405711 0.90 KDM5B (0.39) KDM5BLMNASMN1; SMN2PIK3CAMTOR
SCHEMBL25405325 0.90 KDM5B (0.39) KDM5BLMNASMN1; SMN2PIK3CAMTOR
SCHEMBL23951134 0.89 EPHB4 (0.38) KDM5BRETJAK2JAK1TYK2
SCHEMBL23416850 0.89 KDM5B (0.39) KDM5BRETFGFR1FGFR2FGFR3
SCHEMBL26275735 0.89 KDM5B (0.35) KDM5BPIM1RETJAK2JAK1
SCHEMBL26275739 0.89 KDM5B (0.35) KDM5BPIM1RETJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN claimed
CN-115443276-B Pyridopyrimidinone derivatives and their use as arene receptor modulators 东亚ST株式会社 2025-04-18 CN disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2023-05-11 US disclosed
CN-115443276-A Pyridopyrimidinone derivatives and their use as modulators of aromatic hydrocarbon receptors 东亚ST株式会社 2022-12-06 CN disclosed
WO-2021210970-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS DONG-A ST CO., LTD. (KR) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230147257-A1 PYRIDOPYRIMIDINONE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS AHR, ARNT, AIPL1 KDM5B 743/4885PIM1 3686/4885LMNA 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.